Arrowhead Pharmaceuticals ($ARWR) Stock Hub 2026: REDEMPLO Launch, Positive SHASTA Phase 3 Data, YOSEMITE Enrollment And A $1.78B Liquidity Base

01Executive Summary

Arrowhead Pharmaceuticals ($ARWR) is a Pasadena-based RNA interference (RNAi) company that, in late 2025, made the hardest transition in biotech: from clinical-stage developer to commercial-stage pharmaceutical company. On November 18, 2025, the FDA approved its first wholly-owned medicine, REDEMPLO (plozasiran), an siRNA that silences apoC-III, as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). Arrowhead is launching it independently in the U.S.

The equity story has three layers. The first is the launch: REDEMPLO is early but building momentum — more than 400 prescriptions received or in process and roughly 180 patients shipped as of the May 2026 update, at a $45,000-per-year U.S. list price. The second is successful expansion beyond rare-disease FCS: on July 22, 2026, both registrational Phase 3 studies in severe hypertriglyceridemia, SHASTA-3 and SHASTA-4, met the primary endpoint and all prespecified secondary endpoints. Median triglyceride reductions reached 79% and 81% at month 12, while the pooled analysis showed a statistically significant reduction in acute-pancreatitis events, including a 78% cumulative-event reduction in the broad SHTG population and a 100% reduction in the predefined highest-risk subgroup. MUIR-3 adds safety exposure to the planned regulatory package. The third is a broad platform and balance sheet: a wholly-owned cardiometabolic and obesity franchise, partnered programs with Amgen, Takeda, Sarepta, Novartis, Madrigal and GSK, and roughly $1.78 billion in cash and investments at March 31, 2026.

The positive SHASTA readout materially reduces the clinical uncertainty around the SHTG expansion thesis, but it does not finish the work. Full data still need to be presented and published; Arrowhead must assemble and file the sNDA, obtain regulatory approval, secure reimbursement and execute against Ionis in a much larger commercial market. At the same time, Arrowhead is spending like a company launching a product and funding multiple late-stage and early-stage programs — R&D was $173 million in the fiscal second quarter alone — and carries meaningful obligations including a $700 million convertible note, a Sixth Street credit facility being repaid, and a Royalty Pharma monetization. Revenue today remains dominated by partnership and licensing payments, not product sales.

02Company Overview And The RNAi Platform

Arrowhead develops medicines that treat disease by silencing the specific genes that cause them, using the natural RNA interference mechanism. Its proprietary Targeted RNAi Molecule (TRiM) platform is engineered to deliver small-interfering RNA precisely into a wide range of tissues — not only the liver (where first-generation RNAi drugs were concentrated) but also lung, skeletal muscle, adipose tissue and the central nervous system. That breadth of delivery is the core of Arrowhead’s differentiation and the reason its pipeline spans cardiometabolic, pulmonary, neuromuscular and CNS diseases.

The company’s model has long been a hybrid: advance a set of wholly-owned assets toward the market while out-licensing others to large pharma partners in exchange for upfront cash, milestones and royalties. That strategy funded years of development and has now delivered its first approved product. Following the REDEMPLO approval, Arrowhead describes itself as a commercial-stage company, and its near-term narrative is about executing a launch and expanding a label rather than proving a platform that is now clinically and commercially validated.

Structurally, the important nuance for investors is that Arrowhead’s reported revenue is still overwhelmingly collaboration and licensing income — payments from partners recognized as programs hit milestones — rather than product sales. That makes the top line lumpy from quarter to quarter and means REDEMPLO’s commercial ramp, not the headline revenue number, is the metric to watch as the launch matures.

03REDEMPLO (plozasiran) — The First Approved Product

REDEMPLO (plozasiran) is an siRNA therapeutic designed to suppress the liver’s production of apoC-III, a protein that raises triglycerides by slowing their breakdown and clearance. By silencing apoC-III with a durable, quarterly subcutaneous injection, it produces large, sustained triglyceride reductions. It is the first and only siRNA approved for FCS studied in both genetically confirmed and clinically diagnosed patients.

The approved U.S. label is narrow but foundational: an adjunct to diet to reduce triglycerides in adults with FCS, dosed 25 mg subcutaneously once every three months, with no boxed warning and no contraindications. FCS is a severe rare disease — an estimated several thousand U.S. patients whose triglycerides can run ten to one hundred times normal, carrying a high risk of acute, recurrent and potentially fatal pancreatitis.

The launch so far

Arrowhead is commercializing REDEMPLO independently in the U.S. As of the May 7, 2026 update, the company reported:

• More than 400 prescriptions received and in process to date, described as greater than 40% growth over the prior four weeks.
• Approximately 180 patients had received at least one pre-filled-syringe shipment.
• About 30 new written prescriptions per week, and accelerating.
• Roughly 85% of prescriptions were for patients naive to the APOC3 class — a signal that physicians are finding and treating previously untreated FCS patients, rather than simply switching them from a rival drug.

Arrowhead set the U.S. wholesale acquisition cost at $45,000 per patient per year, a premium to the competing approved APOC3 inhibitor, under a “One-REDEMPLO” unified pricing model intended to hold the same price across FCS and severe hypertriglyceridemia if that broader indication is approved. Outside the U.S., REDEMPLO has received FCS approvals in Australia and China, a Health Canada Notice of Compliance, and an EU marketing authorization valid throughout the European Union issued on June 19, 2026 (announced June 22, 2026). Sanofi is responsible for commercialization in Greater China, while Arrowhead has stated that it intends to commercialize REDEMPLO directly in selected European markets.

04The Real Prize — Plozasiran Label Expansion

FCS is the beachhead, not the market. The major value step is the potential expansion of plozasiran into severe hypertriglyceridemia, a population substantially larger and more heterogeneous than FCS. On July 22, 2026, Arrowhead reported that the two registrational studies designed to support that expansion had both succeeded.

SHASTA-3 and SHASTA-4: these global, double-blind, placebo-controlled Phase 3 trials randomized approximately 750 adults in total to 25 mg plozasiran or placebo once every three months. Both studies met the primary endpoint of change in fasting triglycerides at month 12 and met every prespecified secondary endpoint. Median triglyceride reductions were 79% in SHASTA-3 and 81% in SHASTA-4, versus approximately 27% with placebo.

The readout also delivered the result with the greatest potential clinical importance: a reduction in acute pancreatitis. In the prespecified pooled analysis, plozasiran significantly reduced both the proportion of patients with at least one acute-pancreatitis event (p<0.0221) and the total incidence rate of events (p<0.0077) versus placebo. Across the broad SHTG population — triglycerides above 500 mg/dL, with or without prior pancreatitis — cumulative events were reduced 78%. In the predefined highest-risk subgroup with triglycerides above 880 mg/dL and a prior pancreatitis history, the reported event reduction was 100%. These are company-reported topline results; the complete event counts, exposure-adjusted details, subgroup sizes, confidence intervals and supporting analyses remain important parts of the full presentation.

The safety profile was consistent with prior plozasiran studies. Arrowhead reported no new safety signal, no clinically meaningful differences in routine laboratory measurements, no significant difference from placebo in mean liver-fat content in the prespecified MRI-PDFF subgroup, no clinically meaningful adverse liver-enzyme changes, no hypersensitivity cases and no thrombocytopenia signal. Full safety and efficacy analyses are still ongoing.

MUIR-3: this Phase 3 study enrolled more than 1,400 patients with mixed hyperlipidemia, but its principal regulatory role is to supplement the SHASTA studies with additional safety exposure for the planned SHTG filing. It should not be read as a separate near-term mixed-hyperlipidemia label-expansion catalyst. Arrowhead has also been enrolling SHASTA-5 in patients at high risk of acute pancreatitis, with pancreatitis reduction as the primary endpoint; management previously said it would reassess the value of continuing SHASTA-5 if SHASTA-3/-4 already demonstrated a statistically significant pancreatitis benefit.

Arrowhead intends to use SHASTA-3, SHASTA-4 and MUIR-3 to seek SHTG approvals in multiple geographies, beginning with a U.S. supplemental NDA before the end of 2026. Detailed SHASTA results are scheduled for a HOT LINE Late Breaker at the ESC Congress in Munich on August 30, 2026 at 17:30 CEST, followed by a company conference call and webcast on August 31. Importantly, no SHTG PDUFA date exists yet because the sNDA has not been filed and accepted.

05The Wholly-Owned Cardiometabolic & Obesity Pipeline

Beyond plozasiran, Arrowhead is building a multi-asset cardiometabolic and obesity franchise — the area where it keeps the most economics.

Zodasiran (ARO-ANG3)

Zodasiran silences ANGPTL3, a validated lipid target, and is being advanced in Phase 3 with a focus on homozygous familial hypercholesterolemia (HoFH) in the YOSEMITE study. ANGPTL3 knockdown lowers multiple atherogenic lipids, positioning zodasiran as a second wholly-owned cardiometabolic pillar behind plozasiran.

On July 27, 2026 Arrowhead announced that enrollment in YOSEMITE (NCT07037771) is complete. The global, multicentre, randomised, double-blind, placebo-controlled study enrolled 70 patients against an original design of 60, randomised 2:1 to four quarterly doses of 200 mg zodasiran or placebo. Participants are over the age of 12 and already on maximally tolerated lipid-lowering therapy; the primary endpoint is the percent change in fasting LDL-C from baseline to month 12, with an optional open-label extension afterwards. Study completion is guided to mid-2027, with regulatory submissions in multiple geographies to follow if the data support them.

The mechanistic argument is specific to this population. HoFH is usually caused by mutations in the LDL receptor gene, so therapies that depend on a functioning receptor lose potency exactly where the disease is most severe; reducing ANGPTL3 lowers atherogenic lipoproteins through a different route. Zodasiran carries FDA Orphan Drug Designation for HoFH, and in the Phase 2 GATEWAY study in HoFH patients there were no drug discontinuations, no drug-related serious adverse events and no deaths, with the most frequent adverse events being COVID-19, nasopharyngitis, upper respiratory tract infection and dizziness. Untreated, median LDL-C in HoFH can exceed 400 mg/dL, and estimated global prevalence is between 1 in 360,000 and 1 in 250,000 — a small population, which is what makes the enrollment overshoot notable and also what caps the commercial size of this indication on its own.

Obesity — ARO-INHBE and ARO-ALK7

Arrowhead’s RNAi approach to obesity is one of its most-watched early stories. In interim Phase 1/2a data reported through May 2026:

• ARO-INHBE combined with tirzepatide drove -9.4% weight loss at week 16 in obese patients with type 2 diabetes — roughly double the -4.8% on tirzepatide alone — plus large reductions in visceral, total and liver fat.
• ARO-ALK7 became the first RNAi therapeutic to show knockdown of an adipocyte-expressed gene in humans, achieving a mean -88% reduction in ALK7 mRNA and a -14.1% placebo-adjusted visceral-fat reduction from a single dose.

At EASL 2026, Arrowhead also reported that a single 400 mg dose of ARO-INHBE produced a mean maximum 85.3% reduction in Activin E with an effect persisting beyond three months. In a small subgroup with elevated baseline liver fat, doses of 200 mg or more produced a 44% placebo-adjusted reduction in liver fat; continued improvements in visceral and liver fat were observed from week 12 to week 24. These remain interim, early-stage data from small cohorts.

The thesis is that RNAi could complement or extend incretin (GLP-1/GIP) therapies by improving body composition — preserving the quality of weight loss — with an infrequent dosing schedule.

ARO-DIMER-PA

In the fiscal second quarter Arrowhead dosed the first subjects in a Phase 1/2a trial of ARO-DIMER-PA, described as the first dual-functional RNAi candidate designed to silence two genes (PCSK9 and APOC3) in a single molecule, targeting ASCVD driven by mixed hyperlipidemia — a genuine platform milestone if it translates.

06The Partnership Engine

Much of Arrowhead’s value — and most of its current revenue — sits in a network of large-pharma collaborations. These deals fund the platform and de-risk assets, but they also mean the biggest late-stage readouts are partner-controlled and, in several cases, years away.

The Sarepta question

Because Sarepta had a difficult 2025 in unrelated programs, investors reasonably ask whether the 2024 Arrowhead license — worth $500 million upfront, $325 million in equity, $250 million in annual installments and up to roughly $10 billion in potential milestones — is still solid. Arrowhead addressed this directly in a July 23, 2025 statement confirming the agreement was intact and that it expected Sarepta to meet its obligations. The subsequent filings support that: the near-term ARO-DM1 milestone package was paid, the first $50 million annual installment was received on schedule in February 2026, and a December 2025 clinical-supply agreement is already generating revenue. Contract protections also let Arrowhead terminate the deal if any installment is missed.

07Financials And Runway

At March 31, 2026 Arrowhead held $188.5 million in cash, equivalents and restricted cash and $1,595.6 million in available-for-sale securities and short-term investments — roughly $1,784 million in total cash resources, up from $919 million at fiscal year-end (September 30, 2025) after a large January 2026 financing. Management states it expects sufficient liquidity to fund operations for at least the next twelve months from the May 2026 filing date; it did not publish a specific multi-year runway figure.

*The prior-year quarter was inflated by recognition of the large Sarepta upfront, which is why the year-over-year comparison swings from profit to loss. It reflects revenue-recognition timing, not a deterioration in the business.

The takeaway: the loss reflects a company simultaneously launching a product and funding Phase 3 trials plus a broad discovery engine. Revenue is dominated by collaboration and licensing income and is therefore lumpy; REDEMPLO’s own product revenue is not yet separately disclosed and remains immaterial in the launch quarter. With ~$1.78 billion on hand, the near-term question is commercial and clinical execution, not solvency.

08Capital Structure And Dilution

Arrowhead had roughly 140.9 million basic shares outstanding on the May 1, 2026 10-Q cover (140.6 million on the March 31 balance sheet). That basic count excludes pre-funded warrants. The January 2026 financing included $700 million of 0.00% convertible senior notes due 2032 with an initial conversion price of approximately $87.08, plus an underwritten offering of 2,015,505 common shares at $64.50 and pre-funded warrants for 1,550,387 shares at $64.499, generating $230 million of gross equity proceeds. The company also entered into capped-call transactions with an initial cap price of approximately $119.33 to reduce potential dilution from the convertible notes.

As of March 31, 2026, none of the 1,550,387 pre-funded warrants issued in 2026 had been exercised. A separate set of 917,441 pre-funded warrants issued in 2024, with a $0.001 exercise price, also remained unexercised. These instruments are economically close to common equity and mean the fully diluted share count is higher than the basic share figure used in a simple market-cap calculation.

Arrowhead also maintains an at-the-market offering program of up to $500 million through Jefferies. It sold approximately 689,000 shares during the first fiscal quarter of 2026, producing $48.2 million in gross proceeds and $46.8 million net; no ATM shares were sold during the fiscal second quarter. The remaining ATM capacity is a useful funding option but also a potential source of future dilution.

On the liability side, three items matter. The convertible notes ($681.9 million carrying value) are cheap capital but can create equity dilution under their terms. The Sixth Street credit facility — an August 2024 financing carrying a high 15% payment-in-kind rate — is being actively repaid, down to $199.6 million from $254.9 million. And a Royalty Pharma monetization from 2022 shows up as a $383.8 million “liability related to the sale of future royalties”; it is economically tied to transferred future royalty streams rather than functioning like an ordinary repayable term loan.

09Merlintrader Health Score

Editorial 1–5 score on 12–18 month robustness/fragility across five pillars. It is not a buy/sell signal.

Reading: a first approved product, successful pivotal SHTG data, a deep partnered platform, a funded balance sheet and an unusually dense catalyst calendar anchor the score. Offsets are a complex capital structure (convertible notes, a high-cost credit facility, a royalty monetization), a still-immaterial product ramp, regulatory and commercial work still required for SHTG, and normal clinical risk in the earlier obesity/CNS programs. The 4/5 reflects robustness and optionality, not a buy/sell view. Merlintrader editorial assessment, not advice.

10Competitive Landscape

Arrowhead competes on two fronts: as an RNAi platform and, more concretely, in the triglyceride/apoC-III market it just entered.

In FCS and hypertriglyceridemia, the most direct rival is Ionis Pharmaceuticals‘ olezarsen (Tryngolza), an antisense apoC-III drug approved in the U.S. for FCS ahead of REDEMPLO. Arrowhead’s pitch is a differentiated profile and its quarterly dosing versus more frequent injection, with the premium $45,000 price framed as supported by clinical evidence. Arrowhead has now reported successful Phase 3 SHTG results, including deep triglyceride reductions and a statistically significant pancreatitis signal. The competitive comparison will depend on the detailed SHASTA dataset, label breadth, safety, dosing convenience, pricing, reimbursement, physician adoption and the timing and strength of Ionis’s own SHTG expansion package.

Patent litigation is an additional risk. Arrowhead filed a declaratory-judgment action in September 2025 seeking a ruling that an Ionis patent was invalid and not infringed; that action was dismissed on December 23, 2025. Ionis separately filed a patent-infringement complaint alleging that commercialization of plozasiran infringes the same patent and seeking damages. Arrowhead disputes the allegations and has stated that it intends to defend itself vigorously. The March 31, 2026 10-Q did not record a material contingent liability for the matter, but the case remains a legal overhang tied directly to the lead commercial asset.

In RNAi broadly, Alnylam Pharmaceuticals is the category leader with multiple approved liver-targeted medicines and a large commercial base, while Ionis (antisense) and others compete for the same lipid and rare-disease targets. Arrowhead’s differentiation is the TRiM platform’s reach beyond the liver — into lung, muscle, adipose and CNS — which underpins programs (obesity, neuromuscular, pulmonary) that pure liver-RNAi peers cannot easily match.

In obesity, Arrowhead is a newcomer against the incretin giants (Novo Nordisk, Eli Lilly) and a crowded field of next-generation entrants. Its angle is not to beat GLP-1s head-on but to complement them on body composition with infrequent RNAi dosing — a thesis that still has to prove itself in larger trials.

11Management

Christopher Anzalone, Ph.D., co-founder, is President, Chief Executive Officer and Board Chair, and has led Arrowhead through its long build from platform company to commercial launch. Daniel Apel serves as Chief Financial Officer, James Hamilton, M.D. as Chief Medical Officer and Head of R&D, and Patrick C. O’Brien as Chief Operating Officer.

For a company pivoting to commercial execution while running Phase 3 trials and a heavy business-development cadence, the leadership continuity at the top — and the addition of experienced financial and clinical operators — is a stabilizing factor. (Investor-relations contact is handled by Vince Anzalone, CFA, VP of Investor Relations, who is not the CFO — a common point of confusion.)

12What Bulls See

The constructive case is that Arrowhead has crossed two high-risk thresholds: it has an approved, launching product, and the same asset has now succeeded in two large registrational SHTG studies. Plozasiran’s planned label expansion targets a population many multiples the size of FCS, while the pancreatitis result gives the story a clinically meaningful dimension beyond laboratory triglyceride lowering. The quarterly dosing profile, clean topline safety language and Breakthrough Therapy designation may support a differentiated regulatory and commercial proposition. The wholly-owned obesity programs (ARO-INHBE, ARO-ALK7) add longer-duration upside, while the partnership roster — Amgen, Takeda, Sarepta, Novartis, Madrigal and GSK — validates the platform and can provide milestone and royalty income. With approximately $1.78 billion on hand, bulls argue Arrowhead is entering a multi-year transition from an RNAi platform with a rare-disease launch into a broader cardiometabolic commercial company.

13What Bears See

The skeptical view starts with the gap between a successful clinical package and durable cash flows. REDEMPLO is early and small in FCS: product revenue is not yet separately disclosed, and the launch has to prove it can scale before it materially changes the P&L. The SHTG topline is clearly positive, but Arrowhead still needs to show the full dataset, file an acceptable sNDA, obtain the desired label, win payer access and compete effectively against olezarsen. Meanwhile the company is burning heavily — R&D of $173 million in a single quarter — and reported revenue is dominated by lumpy collaboration income. The capital structure remains more complex than the gross cash suggests: a $700 million convertible, a high-cost Sixth Street facility, pre-funded warrants, an ATM program and a Royalty Pharma monetization all matter. Several other major value drivers remain partner-controlled or early-stage.

Key Red Flags To Monitor

• Launch scale: REDEMPLO revenue is still immaterial and must demonstrate a durable ramp; FCS alone is a small market.
• Full SHASTA dataset: topline results are strong, but detailed event counts, confidence intervals, subgroup sizes, discontinuations and the complete safety dataset remain to be presented and published.
• Regulatory and access risk: the sNDA has not yet been filed or accepted, no SHTG PDUFA date exists, the final label is unknown and payer adoption in a broad chronic population may be demanding.
• Cash burn vs. revenue quality: large R&D spend against lumpy, partnership-driven revenue rather than mature product sales.
• Capital-structure complexity: convertible notes, pre-funded warrants, the still-available ATM, the Sixth Street facility and the Royalty Pharma liability mean fully diluted equity and net financial resources differ materially from the simple basic-share and gross-cash figures.
• Patent litigation: Ionis alleges that commercialization of plozasiran infringes a U.S. patent; Arrowhead disputes the claim, but the case creates legal and potential economic uncertainty around the lead product.
• Partner dependence: marquee late-stage catalysts such as olpasiran and fazirsiran are partner-controlled and years out.
• Competition: Ionis in apoC-III, Alnylam in RNAi and incretin leaders in obesity.

14Scenario Framework

The following scenarios are descriptive ways to think about how the story could evolve. They are not price targets, forecasts or recommendations.

15Bottom Line

Arrowhead Pharmaceuticals has done two difficult things: it turned its RNAi platform into an approved, launching product, and it has now extended that product’s clinical validation into a much larger severe-hypertriglyceridemia population. SHASTA-3 and SHASTA-4 met the primary endpoint and all prespecified secondary endpoints, with 79% and 81% median triglyceride reductions and a statistically significant pooled reduction in acute-pancreatitis events. The reported 78% event reduction in the broad SHTG population and 100% reduction in the predefined highest-risk subgroup make this more than a laboratory-biomarker readout.

The result materially improves the SHTG expansion thesis, but the next phase is execution rather than celebration. Investors still need the detailed ESC dataset, the MUIR-3 safety contribution, the sNDA filing and acceptance, the eventual FDA label, payer access and real-world market uptake. Those tasks sit alongside the existing FCS launch, the Ionis patent dispute, substantial R&D spending, a complex capital structure and a broad pipeline that requires disciplined capital allocation.

For a stock hub, the honest framing remains a scorecard, not a verdict. The three central tracking points are now the REDEMPLO commercial ramp, the August 30–31 detailed SHASTA review and subsequent SHTG regulatory path, and the early obesity/cardiometabolic readouts that determine how far beyond plozasiran the platform can reach. The cash, partnerships and TRiM breadth provide resilience and optionality, but they do not remove execution risk.